NE-ADJUVANCE-TECH
Adjuvance Technologies Inc., a privately held clinical-stage biopharmaceutical company developing saponin adjuvants and vaccines for infectious disease and immuno-oncology, announced that its adjuvant TQL-1055 was safe and well-tolerated with a co-administered pertussis vaccine. This is the first clinical trial of a candidate from the company’s adjuvant and vaccine portfolio.
“The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. Our semi-synthetic molecule is designed to overcome these limitations,” said Tyler Martin M.D., Chief Executive Officer at Adjuvance. “These promising interim results demonstrate the potential of TQL-1055, including its ability to be used in a broader dose-range without compromising its excellent tolerability.”
Interim data from the trial show that TQL-1055 was generally well tolerated across all dose levels, with an overall safety profile similar to a commercial pertussis vaccine. Solicited events reported by subjects included mild to moderate injection site reactions and mild or moderate systemic symptoms at a frequency similar to the commercial vaccine. No serious adverse events were reported.
The ongoing phase 1, randomized, double-blind, active-controlled, dose-escalation study is assessing the safety and immunogenicity of P ertussis A cellular V accine A djuvanted with TQL-1055 (PAVA). It has fully enrolled 72 healthy adults 18-50 years of age and is evaluating six escalating dose levels from 25 to 800 mcg of TQL-1055, co-administered with a commercial pertussis vaccine. The primary endpoints of the study are safety and tolerability. Further data will be presented at IDWeek 2021.
About Pertussis: Commonly known as whooping cough, pertussis is a respiratory illness that spreads from person to person. Vaccination against pertussis occurs throughout life and is recommended in many countries for all children and adults. Reported annual cases of pertussis in the United States have increased 10-fold between the 1970s and 2010s, revealing the need for more effective vaccines and vaccination.
About TQL-1055 : TQL-1055 is a rationally designed, semi-synthetic analogue of the saponin adjuvant QS-21 that is designed to have improved tolerability and provide the same strong immune response as QS-21. Adjuvance has retained the desirable properties of, and eliminated several challenges with QS-21. TQL-1055 is a semi-synthetic molecule whose efficient synthesis uses raw material from leaves and branches of the Quillaja saponaria tree, making it available in greater quantities than the source material for other saponin adjuvants. TQL-1055 has shown favorable tolerability and a strong immune response in a clinical trial. With TQL-1055 as the foundation, Adjuvance is designing new combination adjuvants to produce different types of immune responses.
About saponin adjuvants : Saponin adjuvants are potent immune stimulators and important components of licensed and clinically-advanced infectious disease vaccines including those against shingles, malaria, COVID-19 and influenza. Saponin adjuvants have also been studied in immuno-oncology applications. Existing saponin adjuvants are limited by poor clinical tolerability and inefficient manufacturing requirements. The natural source material in most saponin adjuvants is extracted from the inner lining of the bark of the Quillaja saponaria tree, resulting in a terminal harvest.
About Adjuvance Technologies : Adjuvance Technologies is a privately held clinical-stage biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. Our vaccine candidates in pertussis and herpes zoster aim to provide a better experience for the recipient and the same protection against disease.
Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institute of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005212/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ChipAgents Raises Oversubscribed $21M Series A to Redefine AI for Chip Design21.10.2025 16:30:00 CEST | Press release
Sales 50x YoY, Deployments at 50 leading semiconductor companies. Former CEOs of Cadence and Mentor Graphics, Plus Former Synopsys CTO, Join Advisory Board. Today ChipAgents, the agentic AI platform transforming chip design and verification, announced the close of a $21 million Series A funding round, bringing the total fundraise to $24 million to date. This latest round closed with Bessemer Venture Partners, with strategic backing from Micron, MediaTek, Ericsson, and additional top semiconductor companies. Also participating in the round are notable angels including new advisors, Wally Rhines, Raúl Camposano,and Jack Harding, and existing support by ScOp Venture Capital (Ivan Bercovich) and Amino Capital, fueling the company’s expansion of product development, customer acquisition, and strategic industry partnerships. ChipAgents’ mission is to bring the power of AI to the heart of chip design and verification. Every engineer should be empowered with tools that make the most complex as
STARLIMS Launches QM Essentials LIMS, the Best Cloud LIMS for SMB Batch Manufacturing21.10.2025 15:13:00 CEST | Press release
STARLIMS, a global leader in Laboratory Information Management Systems (LIMS) and informatics solutions, today announced Quality Manufacturing (QM) Essentials, a new cloud-based LIMS developed for small and mid-sized (SMB) batch manufacturers to bring products to market quickly and more cost-effectively. The launch reflects STARLIMS’ commitment to meeting the unique needs of smaller batch manufacturing organizations who need the power of a LIMS without the cost or complexity of a large-scale implementation. Built for pharmaceutical, food & beverage, and consumer product industries, QM Essentials allows SMBs to simplify compliance and expedite batch release with an out-of-the-box solution that can be deployed in as little as 4-6 weeks. A Cost-Effective SaaS LIMS with Less Complexity Pre-configured and pre-loaded with essential features such as batch login, environmental monitoring, outsource samples, and static data, QM Essentials is a Software-as-a-Service (SaaS) LIMS that allows SMB l
Lenovo Unlocks New Level of Productivity and Creativity with Copilot+ PCs Powered by AMD Ryzen™ AI Processors21.10.2025 15:00:00 CEST | Press release
Selection of ThinkCentre neo desktops ready to take small and medium-sized businesses into the next era of AI performance Lenovo™ unveiled its new generation of ThinkCentre™ desktop next-gen AI PCs powered by AMD Ryzen™ AI 300 Series processors with up to 50 TOPS of integrated NPU capability: the streamlined ThinkCentre neo 55a Gen 6 all-in-one (AIO), the small form factor ThinkCentre neo 55s Gen 6, and the tiny ThinkCentre neo 55q Gen 6. Designed for small and medium-sized businesses looking to supercharge their productivity with AI, the ThinkCentre neo Gen 6 desktop family offers unique Copilot+ PC experiences1, the performance to excel, the flexibility and expandability to adapt, and the efficiency and support for peace of mind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021383117/en/ ThinkCentre™ desktop next-gen AI PCs powered by AMD Ryzen™ AI 300 Series processors “AI has, is, and will continue to reshape the wa
Hologic to be Acquired by Blackstone and TPG for up to $79 per Share21.10.2025 14:41:00 CEST | Press release
Hologic Stockholders to Receive $76 per Share in Cash Plus a Contingent Value Right of up to $3 per Share Payable Upon Achieving Certain Revenue MilestonesRepresents 46% Premium to Hologic’s Closing Price on Last Trading Day Prior to Media Reports of Possible TransactionTransaction Includes Significant Minority Investments from ADIA and GICTransaction Will Help Hologic Strengthen its Leadership in Women’s Health and Accelerate Growth Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into a definitive agreement to be acquired by funds managed by Blackstone (“Blackstone”) and TPG in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3 billion.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021765122/en/ Under the terms of the agreement, Blackstone and TPG will acquire all outstanding Hologic shares for $76 per share in cash plus a non-tradable contingent value right (C
Axelera Announces Europa AIPU, Setting New Industry Benchmark for AI Accelerator Performance, Power Efficiency and Affordability21.10.2025 14:00:00 CEST | Press release
Delivers 629 TOPs processing power for multi-modal AI applications from the edge to the data center Axelera AI, the leading provider of purpose-built AI hardware acceleration technology, today announced Europa™, an AI processor unit (AIPU) that sets a new performance/price standard for multi-user generative AI and computer vision applications. Europa’s combination of processing power, energy and thermal efficiency, compact packaging, and multiple form factor options make it ideal for compute-intensive, multi-modal AI inference applications from the edge to enterprise servers. Designed to be cost effective and accessible, Europa enables any organization to unlock the power of cutting-edge AI applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021493990/en/ Europa™ AIPU Next Gen Architecture for Real World AI Processing Power The Europa AIPU features eight second-generation AI cores, each incorporating Axelera’s ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom